Global Hereditary Angioedema Drug market is expected to grow from US$ 850 million in 2025 to US$ 1280 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.

Global Hereditary Angioedema Drug Market Size and Outlook 2025-31

The global Hereditary Angioedema Drug market size is predicted to grow from US$ 850 million in 2025 to US$ 1280 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Hereditary Angioedema Drug Industry Forecast looks at past sales and reviews total world Hereditary Angioedema Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hereditary Angioedema Drug sales for 2025 through 2031. With Hereditary Angioedema Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hereditary Angioedema Drug industry. This Insight Report provides a comprehensive analysis of the global Hereditary Angioedema Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hereditary Angioedema Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Hereditary Angioedema Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hereditary Angioedema Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hereditary Angioedema Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Hereditary Angioedema Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; C1 Esterase Inhibitor &nbsp;&nbsp;&nbsp; Kallikrein Inhibitor &nbsp;&nbsp;&nbsp; Selective Bradykinin B2 Receptor Antagonist Segmentation by Application: &nbsp;&nbsp;&nbsp; Retail Pharmacies &nbsp;&nbsp;&nbsp; Hospital Pharmacies &nbsp;&nbsp;&nbsp; Online Pharmacies This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Pharming Group NV &nbsp;&nbsp;&nbsp; Takeda &nbsp;&nbsp;&nbsp; CSL Limited &nbsp;&nbsp;&nbsp; IBio Inc. &nbsp;&nbsp;&nbsp; BioCryst Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Ionis Pharmaceuticals, Inc. Key Questions Addressed in this Report What is the 10-year outlook for the global Hereditary Angioedema Drug market? What factors are driving Hereditary Angioedema Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Hereditary Angioedema Drug market opportunities vary by end market size? How does Hereditary Angioedema Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Hereditary Angioedema Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Hereditary Angioedema Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Hereditary Angioedema Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Hereditary Angioedema Drug Segment by Type &nbsp;2.2.1 C1 Esterase Inhibitor &nbsp;2.2.2 Kallikrein Inhibitor &nbsp;2.2.3 Selective Bradykinin B2 Receptor Antagonist &nbsp;2.3 Hereditary Angioedema Drug Sales by Type &nbsp;2.3.1 Global Hereditary Angioedema Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Hereditary Angioedema Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Hereditary Angioedema Drug Sale Price by Type (2020-2025) &nbsp;2.4 Hereditary Angioedema Drug Segment by Application &nbsp;2.4.1 Retail Pharmacies &nbsp;2.4.2 Hospital Pharmacies &nbsp;2.4.3 Online Pharmacies &nbsp;2.5 Hereditary Angioedema Drug Sales by Application &nbsp;2.5.1 Global Hereditary Angioedema Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Hereditary Angioedema Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Hereditary Angioedema Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Hereditary Angioedema Drug Breakdown Data by Company &nbsp;3.1.1 Global Hereditary Angioedema Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Hereditary Angioedema Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Hereditary Angioedema Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Hereditary Angioedema Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Hereditary Angioedema Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Hereditary Angioedema Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Hereditary Angioedema Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Hereditary Angioedema Drug Product Location Distribution &nbsp;3.4.2 Players Hereditary Angioedema Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Hereditary Angioedema Drug by Geographic Region &nbsp;4.1 World Historic Hereditary Angioedema Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Hereditary Angioedema Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Hereditary Angioedema Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Hereditary Angioedema Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Hereditary Angioedema Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Hereditary Angioedema Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Hereditary Angioedema Drug Sales Growth &nbsp;4.4 APAC Hereditary Angioedema Drug Sales Growth &nbsp;4.5 Europe Hereditary Angioedema Drug Sales Growth &nbsp;4.6 Middle East & Africa Hereditary Angioedema Drug Sales Growth 5 Americas &nbsp;5.1 Americas Hereditary Angioedema Drug Sales by Country &nbsp;5.1.1 Americas Hereditary Angioedema Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Hereditary Angioedema Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Hereditary Angioedema Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Hereditary Angioedema Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Hereditary Angioedema Drug Sales by Region &nbsp;6.1.1 APAC Hereditary Angioedema Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Hereditary Angioedema Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Hereditary Angioedema Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Hereditary Angioedema Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Hereditary Angioedema Drug by Country &nbsp;7.1.1 Europe Hereditary Angioedema Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Hereditary Angioedema Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Hereditary Angioedema Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Hereditary Angioedema Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Hereditary Angioedema Drug by Country &nbsp;8.1.1 Middle East & Africa Hereditary Angioedema Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Hereditary Angioedema Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Hereditary Angioedema Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Hereditary Angioedema Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Hereditary Angioedema Drug &nbsp;10.3 Manufacturing Process Analysis of Hereditary Angioedema Drug &nbsp;10.4 Industry Chain Structure of Hereditary Angioedema Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Hereditary Angioedema Drug Distributors &nbsp;11.3 Hereditary Angioedema Drug Customer 12 World Forecast Review for Hereditary Angioedema Drug by Geographic Region &nbsp;12.1 Global Hereditary Angioedema Drug Market Size Forecast by Region &nbsp;12.1.1 Global Hereditary Angioedema Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Hereditary Angioedema Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Hereditary Angioedema Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Hereditary Angioedema Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Pharming Group NV &nbsp;13.1.1 Pharming Group NV Company Information &nbsp;13.1.2 Pharming Group NV Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.1.3 Pharming Group NV Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Pharming Group NV Main Business Overview &nbsp;13.1.5 Pharming Group NV Latest Developments &nbsp;13.2 Takeda &nbsp;13.2.1 Takeda Company Information &nbsp;13.2.2 Takeda Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.2.3 Takeda Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Takeda Main Business Overview &nbsp;13.2.5 Takeda Latest Developments &nbsp;13.3 CSL Limited &nbsp;13.3.1 CSL Limited Company Information &nbsp;13.3.2 CSL Limited Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.3.3 CSL Limited Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 CSL Limited Main Business Overview &nbsp;13.3.5 CSL Limited Latest Developments &nbsp;13.4 IBio Inc. &nbsp;13.4.1 IBio Inc. Company Information &nbsp;13.4.2 IBio Inc. Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 IBio Inc. Main Business Overview &nbsp;13.4.5 IBio Inc. Latest Developments &nbsp;13.5 BioCryst Pharmaceuticals, Inc. &nbsp;13.5.1 BioCryst Pharmaceuticals, Inc. Company Information &nbsp;13.5.2 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 BioCryst Pharmaceuticals, Inc. Main Business Overview &nbsp;13.5.5 BioCryst Pharmaceuticals, Inc. Latest Developments &nbsp;13.6 Ionis Pharmaceuticals, Inc. &nbsp;13.6.1 Ionis Pharmaceuticals, Inc. Company Information &nbsp;13.6.2 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications &nbsp;13.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Ionis Pharmaceuticals, Inc. Main Business Overview &nbsp;13.6.5 Ionis Pharmaceuticals, Inc. Latest Developments 14 Research Findings and Conclusion

Report	Global Hereditary Angioedema Drug Market Growth 2025-2031
Selected License	Multi ID: LPI24913

Buyer Information

Order Summary